BAY 12-9566
BAY 12-9566 is a non-peptidic biphenyl inhibitor of matrix metalloproteinases (MMPs), primarily studied for its potential to treat various types of cancer, including osteosarcoma and other malignancies.
Mechanism of action
[edit]BAY 12-9566 works by inhibiting matrix metalloproteinases, which are enzymes involved in the breakdown of the extracellular matrix. This process is often implicated in cancer metastasis, as it allows tumor cells to invade surrounding tissues. By inhibiting MMP activity, BAY 12-9566 aims to slow tumor progression and prevent metastasis.[1]
Clinical trials
[edit]BAY 12-9566 was evaluated in clinical trials as part of combination therapies with doxorubicin and other chemotherapeutic agents. In a randomized study with osteosarcoma in dogs, the compound did not significantly improve survival compared to placebo.[1] A Phase III trial involving patients with advanced non-small-cell lung cancer (NSCLC) found limited efficacy when used in combination with chemotherapy.[2]
Applications and limitations
[edit]While BAY 12-9566 demonstrated promising preclinical results, it was ultimately discontinued in human trials due to lack of efficacy. Its primary limitation is related to its inability to significantly prolong survival or reduce tumor size in treated patients, as observed in clinical studies.[3]
References
[edit]- ^ a b Moore, A. S. (2007). "Doxorubicin and BAY 12-9566 for the treatment of osteosarcoma in dogs: a randomized, double-blind, placebo-controlled study". J Vet Intern Med. 21 (4): 783–790. doi:10.1892/0891-6640(2007)21[783]2.0.co;2.
- ^ Christensen, J. G. (2001). "The role of BAY 12-9566 in cancer treatment: a Phase III clinical study". Clin Cancer Res. 7 (5): 1173–1179. doi:10.1200/JCO.2001.19.6.1659.
- ^ Giaccone, G. (2002). "A Phase III clinical study of BAY 12-9566 in patients with advanced non-small-cell lung cancer". J Clin Oncol. 19 (6): 1659–1668. doi:10.1200/JCO.2001.19.6.1659.
 | This article needs additional or more specific categories. (September 2024) |